Qlaris Bio Appoints Fred Guerard, PharmD, as President and CEO

Published on March 12, 2026
DEDHAM, Mass.—Qlaris Bio, Inc., a clinical-stage biotechnology company developing first-in-class therapies for glaucoma including a novel vasodilatory topical ATP-sensitive potassium channel modulator called QLS-111, has announced the appointment of Fred Guerard, PharmD, as its new president and CEO, effective March 1, 2026. The company said he has also joined its board of directors. Dr. Guerard succeeds Thurein Htoo, who will remain with the company through April 1, 2026, to support a seamless leadership transition, according to the announcement.
Continue reading on website
Other news

The McGee Group Celebrates 50 Years in Business, Hosts Celebration at Vision Expo

March 12, 2026
MARIETTA, Ga.—The McGee Group announced that it is celebrating its 50th anniversary this year, marking five decades of dedication to product quality, customer service and excellence in the optical industry. A family-owned company, The McGee Group was founded as a home-based startup in 1976 and has grown to an internationally recognized optical resource today with an 11-brand portfolio including li

National Vision Announces Winners of 11th Annual Scholarship Program

March 12, 2026
DULUTH, Ga.—National Vision Holdings, Inc. (NASDAQ: EYE), has announced the winners of its 11th annual scholarship program, awarding a total of $12,500 in scholarships to three optometry students. With these scholarships, National Vision said it aims to support and inspire the next generation of optometrists. The program invites optometry students to submit essays or videos examining a key topic t